

Jane F Apperley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3214186/publications.pdf>

Version: 2024-02-01

204
papers

12,872
citations

66234

42
h-index

25716

108
g-index

205
all docs

205
docs citations

205
times ranked

11017
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of quantitative polymerase chain reaction for <i>BCR-ABL1</i> transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with <i>e14a2</i> transcripts an artefact of technology?. <i>British Journal of Haematology</i> , 2022, 197, 52-62.	1.2	7
2	The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
3	Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	1
4	Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2022, 197, .	1.2	13
5	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211
6	Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13). <i>American Journal of Hematology</i> , 2021, 96, 163-164.	2.0	6
7	Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy. <i>British Journal of Haematology</i> , 2021, 192, 137-145.	1.2	6
8	Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. <i>Oncogene</i> , 2021, 40, 2697-2710.	2.6	20
9	Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. <i>Cancers</i> , 2021, 13, 2155.	1.7	4
10	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 686-693.	0.2	2
11	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. <i>Leukemia</i> , 2021, 35, 2885-2894.	3.3	153
12	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2042-2050.	0.6	95
13	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	0.6	147
14	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 684659.	1.8	14
15	Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis. <i>Cancers</i> , 2021, 13, 4863.	1.7	1
16	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 346-355.	1.2	18
17	Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP). <i>Blood</i> , 2021, 138, 3959-3959.	0.6	0
18	Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. <i>Blood</i> , 2021, 138, 2550-2550.	0.6	8

#	ARTICLE	IF	CITATIONS
19	Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2021, 138, 3954-3954.	0.6	0
20	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 131-142.	0.6	14
21	Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. <i>Leukemia</i> , 2020, 34, 667-670.	3.3	10
22	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e50-e60.	2.2	53
23	Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 584607.	1.3	0
24	A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 171-193.	1.2	38
25	An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets. <i>British Journal of Haematology</i> , 2020, 190, e236-e239.	1.2	0
26	Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	1.1	29
27	Prolonged treatment-free remission in chronic myeloid leukemia patients with previous <i>BCR-ABL1</i> kinase domain mutations. <i>Haematologica</i> , 2020, 105, e225-e227.	1.7	7
28	Expert opinion on management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. <i>Leukemia</i> , 2020, 34, 1495-1502.	3.3	63
29	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	2.6	30
30	Ruxolitinib for tocilizumab refractory severe COVID-19 infection. <i>British Journal of Haematology</i> , 2020, 190, e198-e200.	1.2	37
31	Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1763-1772.	1.3	14
32	Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. <i>Bone Marrow Transplantation</i> , 2020, 55, 1840-1843.	1.3	3
33	Phase 1 Trial of Vodobotinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. <i>Blood</i> , 2020, 136, 51-52.	0.6	20
34	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
37	The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 3333-3334.	0.6	2
38	De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e375-e383.	2.2	129
39	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1835-1850.	3.3	97
40	Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1. <i>Leukemia and Lymphoma</i> , 2019, 60, 3090-3091.	0.6	1
41	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2322-2329.	2.0	21
42	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. <i>Haematologica</i> , 2019, 104, 2400-2409.	1.7	37
43	MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. <i>Haematologica</i> , 2019, 104, 2206-2214.	1.7	10
44	What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 477-479.	1.2	5
45	Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 197-199.	1.1	15
46	Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. <i>Clinical Nutrition</i> , 2019, 38, 738-744.	2.3	37
47	Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study. <i>Blood</i> , 2019, 134, 320-320.	0.6	3
48	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. <i>Blood</i> , 2019, 134, 498-498.	0.6	11
49	Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing 3 Prior TKI Therapies: Initial Safety and Efficacy. <i>Blood</i> , 2019, 134, 4158-4158.	0.6	10
50	NF- κ B-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib. <i>Blood</i> , 2019, 134, 2923-2923.	0.6	1
51	Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling. <i>Blood Cancer Journal</i> , 2018, 8, 24.	2.8	5
52	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 778-785.	2.0	21
53	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 930-936.	2.0	11
54	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. <i>Haematologica</i> , 2018, 103, 514-521.	1.7	70

#	ARTICLE	IF	CITATIONS
55	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	0.6	392
56	C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early and long-term mortality. <i>British Journal of Haematology</i> , 2018, 180, 889-892.	1.2	6
57	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. <i>Journal of Hematology and Oncology</i> , 2018, 11, 143.	6.9	52
58	The argument for using imatinib in CML. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 161-167.	0.9	34
59	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61
60	Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. <i>Blood</i> , 2018, 132, 457-457.	0.6	10
61	DNA-Based Digital PCR for the Quantification of Residual Disease in CML – Sensitivity or Specificity?. <i>Blood</i> , 2018, 132, 1738-1738.	0.6	0
62	Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience. <i>Blood</i> , 2018, 132, 3417-3417.	0.6	0
63	BK-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2017, 98, 632-634.	1.1	36
64	RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia. <i>Clinical Chemistry</i> , 2017, 63, 525-531.	1.5	66
65	Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. <i>Biomolecular Detection and Quantification</i> , 2017, 11, 4-20.	7.0	33
66	Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. <i>Cell Reports</i> , 2017, 18, 1687-1698.	2.9	15
67	E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2017, 102, e297-e299.	1.7	42
68	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. <i>Cancer</i> , 2017, 123, 2875-2880.	2.0	79
69	Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. <i>Nature</i> , 2017, 541, 81-86.	13.7	743
70	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. <i>Blood</i> , 2017, 129, 1548-1556.	0.6	340
71	Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 167-172.	0.6	27
72	De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e310-e316.	2.2	97

#	ARTICLE	IF	CITATIONS
73	Polymorphism in TCFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. <i>Haematologica</i> , 2016, 101, 382-390.	1.7	6
74	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , 2016, 101, 541-558.	1.7	92
75	Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. <i>Stem Cell Reports</i> , 2016, 6, 787-797.	2.3	172
76	Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia. <i>American Journal of Hematology</i> , 2016, 91, E480-E481.	2.0	7
77	Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia. <i>Leukemia Research</i> , 2016, 49, 47-50.	0.4	4
78	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2016, 34, 501-508.	0.8	78
79	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 23-26.	2.0	70
80	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S15-S18.	2.0	47
81	Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. <i>Annals of Hematology</i> , 2016, 95, 967-972.	0.8	6
82	Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 176-189.	1.2	34
83	Allogeneic transplantation for CML in the TKI era: striking the right balance. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 79-91.	12.5	38
84	Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy. <i>Blood</i> , 2016, 128, 1223-1223.	0.6	2
85	Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Blood</i> , 2016, 128, 2226-2226.	0.6	1
86	Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation. <i>Blood</i> , 2016, 128, 5726-5726.	0.6	3
87	Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience. <i>Blood</i> , 2016, 128, 5741-5741.	0.6	2
88	The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions. <i>Blood</i> , 2016, 128, 5987-5987.	0.6	1
89	Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study. <i>Blood</i> , 2016, 128, 938-938.	0.6	5
90	Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3411-3411.	0.6	0

#	ARTICLE	IF	CITATIONS
91	An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2016, 128, 3497-3497.	0.6	0
92	The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia. <i>Blood</i> , 2016, 128, 5435-5435.	0.6	3
93	RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia. <i>Blood</i> , 2016, 128, 3104-3104.	0.6	0
94	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. <i>Blood</i> , 2016, 128, 3374-3374.	0.6	0
95	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2015, 2, 2101-2109.	2.7	36
96	The impact of dasatinib on pregnancy outcomes. <i>American Journal of Hematology</i> , 2015, 90, 1111-1115.	2.0	98
97	A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. <i>Genome Medicine</i> , 2015, 7, 128.	3.6	7
98	CML and tyrosine kinase inhibition: the hope becomes reality. <i>Lancet Haematology</i> , the, 2015, 2, e176-e177.	2.2	7
99	Thyroid Function Abnormalities Associated with Ponatinib Therapy in Patients with Chronic Myeloid Leukemia. <i>Thyroid</i> , 2015, 25, 706-707.	2.4	4
100	Managing pregnancy in chronic myeloid leukaemia. <i>Annals of Hematology</i> , 2015, 94, 167-176.	0.8	71
101	The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML). <i>Blood</i> , 2015, 126, 2795-2795.	0.6	4
102	Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. <i>Blood</i> , 2015, 126, 4024-4024.	0.6	7
103	Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. <i>Blood</i> , 2015, 126, 53-53.	0.6	0
104	Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2014, 99, 1492-1498.	1.7	19
105	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. <i>Blood</i> , 2014, 123, 3574-3577.	0.6	118
106	Chronic Myeloid Leukemia—Transplantation in the Tyrosine Kinase Era. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1037-1053.	0.9	12
107	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , 2014, 124, 738-738.	0.6	6
108	Clinical Outcome Following Change of Tyrosine Kinase Inhibitor (TKI) According to the Detection of an ABL Kinase Mutation. <i>Blood</i> , 2014, 124, 4557-4557.	0.6	0

#	ARTICLE	IF	CITATIONS
109	MiR-300 Acts As a Tumor Suppressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/ β -Catenin Interplay. <i>Blood</i> , 2014, 124, 4529-4529.	0.6	0
110	Androgen Function in Long-Term Survivors of Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3957-3957.	0.6	0
111	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
112	Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7048-7048.	0.8	9
113	Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party. <i>Blood</i> , 2013, 122, 4632-4632.	0.6	0
114	Use Of a Quality Management System and Outcome After Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 2945-2945.	0.6	1
115	Stem cell transplantation: its importance today. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 277-280.	0.3	0
116	Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: Innovation, automation, and harmonization. <i>American Journal of Hematology</i> , 2012, 87, 717-720.	2.0	14
117	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. <i>Blood</i> , 2012, 120, 163-163.	0.6	34
118	Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML.. <i>Blood</i> , 2012, 120, 2798-2798.	0.6	3
119	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. <i>Blood</i> , 2012, 120, 3747-3747.	0.6	6
120	Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. <i>Blood</i> , 2012, 120, 3749-3749.	0.6	2
121	Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. <i>Blood</i> , 2012, 120, 3763-3763.	0.6	5
122	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq000 rgBT \$Overlock 1	0.6	0
123	PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6503-6503.	0.8	5
124	Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma. <i>Blood</i> , 2012, 120, 4548-4548.	0.6	0
125	Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 4554-4554.	0.6	0
126	A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.. <i>Blood</i> , 2012, 120, 2555-2555.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation. <i>Blood</i> , 2011, 118, 109-109.	0.6	27
128	Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations. <i>Blood</i> , 2011, 118, 4052-4052.	0.6	0
129	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. <i>Blood</i> , 2011, 118, 1932-1932.	0.6	0
130	Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1945-1945.	0.6	0
131	Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2010, 115, 4018-4020.	0.6	56
132	Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. <i>Blood</i> , 2010, 116, 5497-5500.	0.6	65
133	Imatinib "should we have more of a good thing?". <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 303-304.	12.5	1
134	Efficacy and outcome of autologous transplantation in rare myelomas. <i>Haematologica</i> , 2010, 95, 2126-2133.	1.7	51
135	High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. <i>Blood</i> , 2010, 116, 2539-2539.	0.6	1
136	The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis. <i>Blood</i> , 2010, 116, 3410-3410.	0.6	2
137	Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy. <i>Blood</i> , 2010, 116, 3414-3414.	0.6	6
138	Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs. <i>Blood</i> , 2010, 116, 2274-2274.	0.6	1
139	KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. <i>Blood</i> , 2010, 116, 888-888.	0.6	0
140	2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection. <i>Blood</i> , 2010, 116, 677-677.	0.6	0
141	Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 3515-3515.	0.6	0
142	A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls. <i>Blood</i> , 2010, 116, 1697-1697.	0.6	0
143	Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 3488-3488.	0.6	0
144	Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. <i>Blood</i> , 2010, 116, 2348-2348.	0.6	1

#	ARTICLE	IF	CITATIONS
145	DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study. Blood, 2010, 116, 2397-2397.	0.6	0
146	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 2009, 27, 3472-3479.	0.8	181
147	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009, 27, 6041-6051.	0.8	1,188
148	CML in pregnancy and childhood. Best Practice and Research in Clinical Haematology, 2009, 22, 455-474.	0.7	62
149	Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.. Blood, 2009, 114, 1229-1229.	0.6	2
150	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.. Blood, 2009, 114, 3290-3290.	0.6	10
151	Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.. Blood, 2009, 114, 1781-1781.	0.6	0
152	BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.. Blood, 2009, 114, 3248-3248.	0.6	0
153	The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure.. Blood, 2009, 114, 2147-2147.	0.6	0
154	Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.. Blood, 2009, 114, 3392-3392.	0.6	4
155	Uptake and Outcome of Artificial Reproductive Techniques Following Allogeneic Stem Cell Transplantation: A Single Centre Experience.. Blood, 2009, 114, 2257-2257.	0.6	0
156	A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC.. Blood, 2009, 114, 1205-1205.	0.6	5
157	T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.. Blood, 2009, 114, 2214-2214.	0.6	0
158	Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma.. Blood, 2009, 114, 2840-2840.	0.6	0
159	The effects of imatinib on pregnancy outcome. Blood, 2008, 111, 5505-5508.	0.6	328
160	Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study. Blood, 2008, 112, 3229-3229.	0.6	14
161	Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival. Blood, 2008, 112, 332-332.	0.6	7
162	Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.. Blood, 2008, 112, 970-970.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis. <i>Blood</i> , 2008, 112, 188-188.	0.6	12
164	Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3113-3113.	0.6	0
165	Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2008, 112, 3319-3319.	0.6	0
166	Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. <i>Lancet Oncology</i> , The, 2007, 8, 1018-1029.	5.1	590
167	Part II: Management of resistance to imatinib in chronic myeloid leukaemia. <i>Lancet Oncology</i> , The, 2007, 8, 1116-1128.	5.1	101
168	Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.. <i>Blood</i> , 2007, 110, 1037-1037.	0.6	2
169	Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.. <i>Blood</i> , 2007, 110, 1045-1045.	0.6	1
170	Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis.. <i>Blood</i> , 2007, 110, 2945-2945.	0.6	3
171	C-Reactive Protein on Admission Predicts Transplant-Related Mortality in Recipients of Allogeneic Stem Cell Transplant.. <i>Blood</i> , 2007, 110, 3005-3005.	0.6	7
172	Severe Donor Events after Allogeneic Hematopoietic Stem Cell Donation.. <i>Blood</i> , 2007, 110, 3276-3276.	0.6	1
173	Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).. <i>Blood</i> , 2007, 110, 470-470.	0.6	17
174	Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.. <i>Blood</i> , 2007, 110, 471-471.	0.6	7
175	Primary Plasma Cell Leukaemia and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 731-731.	0.6	0
176	For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.. <i>Blood</i> , 2007, 110, 323-323.	0.6	6
177	Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).. <i>Blood</i> , 2007, 110, 464-464.	0.6	0
178	Philadelphia Negative BCR/ABL1 Positive CML: FISH Mapping and aCGH Reveal Breakpoint Hotspots.. <i>Blood</i> , 2007, 110, 2924-2924.	0.6	16
179	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006, 108, 1809-1820.	0.6	1,184
180	Never say never again!. <i>Blood</i> , 2006, 108, 786-787.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. <i>Clinical Research in Cardiology</i> , 2006, 95, 671-674.	1.5	14
182	Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 226-232.	0.9	9
183	A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML).. <i>Blood</i> , 2006, 108, 54-54.	0.6	5
184	A Randomized Single-blind Study of Extracorporeal Photopheresis with UVADEXA® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.. <i>Blood</i> , 2006, 108, 758-758.	0.6	3
185	Impact of HLA Class I and Class II DNA High-Resolution HLA Typing on Outcome in Adult Unrelated Stem Cell Transplantation after In Vivo T-Cell Depletion with CAMPATH 1H: A Single Centre Experience in 100 Patients.. <i>Blood</i> , 2005, 106, 1804-1804.	0.6	2
186	Use of Direct Sequence PCR for ABL Kinase Mutations in Patients with CML Blast Crisis, Treated Prior to the Availability of Imatinib Therapy.. <i>Blood</i> , 2005, 106, 2002-2002.	0.6	3
187	Treatment of Steroid-Resistant Acute GvHD with OKT3 and High-Dose Steroids Versus High-Dose Steroids Alone.. <i>Blood</i> , 2005, 106, 141-141.	0.6	4
188	Long-Term Outcome after LACE (Lomustine, Ara-C, Cyclophosphamide, Etoposide) Conditioned Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin's Lymphoma: A Single Centre Experience.. <i>Blood</i> , 2005, 106, 5502-5502.	0.6	0
189	A Phase II Multicenter Trial of HSV-TK Engineered Donor Lymphocytes after Haplo-Identical HSCT: Early Immune Reconstitution and Abrogation of Gvhd.. <i>Blood</i> , 2004, 104, 436-436.	0.6	10
190	A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with UVADEXA® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1230-1230.	0.6	0
191	Anti-Angiogenic Effect of Bortezomib in Multiple Myeloma Patients.. <i>Blood</i> , 2004, 104, 4912-4912.	0.6	1
192	Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta. <i>New England Journal of Medicine</i> , 2002, 347, 481-487.	13.9	623
193	Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. <i>Blood</i> , 2001, 97, 1232-1240.	0.6	271
194	HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 2001, 114, 36-41.	1.2	17
195	T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. <i>British Journal of Haematology</i> , 2001, 114, 624-631.	1.2	73
196	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. <i>British Journal of Haematology</i> , 2001, 115, 569-574.	1.2	66
197	Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma. <i>Cancer Gene Therapy</i> , 2000, 7, 954-962.	2.2	13
198	Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrow and mobilised peripheral blood. <i>European Journal of Haematology</i> , 2000, 64, 85-92.	1.1	8

#	ARTICLE	IF	CITATIONS
199	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. <i>Blood</i> , 2000, 96, 86-90.	0.6	62
200	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Blood</i> , 2000, 96, 2712-2716.	0.6	243
201	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Blood</i> , 2000, 96, 2712-2716.	0.6	0
202	Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH-296. <i>British Journal of Haematology</i> , 1999, 107, 401-408.	1.2	3
203	HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. <i>British Journal of Haematology</i> , 1992, 81, 383-390.	1.2	44
204	Philadelphia-positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia. <i>American Journal of Hematology</i> , 1986, 22, 199-204.	2.0	27